Denali Therapeutics (DNLI) Cash from Operations (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Cash from Operations data on file, last reported at 131204000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations changed 0.2% year-over-year to 131204000.0 in Q1 2026; TTM through Mar 2026 was 412336000.0, a 12.8% decrease from a year earlier, with the FY2025 full-year figure at 412600000.0, down 18.67% from the prior year.
• Cash from Operations for Q1 2026 stood at 131204000.0, down from 98538000.0 in the prior quarter.
• Over the last five years, Cash from Operations for DNLI reached as high as 42898000.0 in Q2 2022 and fell as low as 131468000.0 in Q1 2025.
• Historically, Cash from Operations has averaged 87894411.76 across 5 years, with a median of 87363000.0 in 2023.
• Across the five-year window, Cash from Operations sank 163.81% in 2023 and surged 32.31% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 72663000.0 in 2022, then slumped by 35.77% to 98657000.0 in 2023, then increased by 15.15% to 83715000.0 in 2024, then fell by 17.71% to 98538000.0 in 2025, then sank by 33.15% to 131204000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 131204000.0 in Q1 2026, 98538000.0 in Q4 2025, and 107296000.0 in Q3 2025.